Ivonescimab and ADG126 for Colorectal Cancer

This trial aims to find the safest and most effective dose of a new treatment combination for advanced or metastatic colorectal cancer that is microsatellite stable (MSS). The study will test different combinations of the investigational drugs ADG126 and ivonescimab, with some groups also receiving additional chemotherapy drugs. This research focuses on harnessing the immune system and stopping tumor growth by targeting cancer cells and blocking new blood vessel formation. People diagnosed with MSS colorectal cancer that has spread and who have previously undergone certain cancer treatments may be a good fit for this study. As a Phase 1 trial, this research seeks to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but it does prohibit certain treatments like chemotherapy, radiation, and some other anti-cancer therapies within a specific time before starting the trial. It's best to discuss your current medications with the trial team to see if any adjustments are needed.

Research suggests that using ivonescimab and ADG126 together might be safe for treating colorectal cancer. Studies are examining patient tolerance to these treatments, aiming to find the best dose with the fewest side effects. These treatments can be administered alone or with other drugs like leucovorin, fluorouracil, and irinotecan, which are commonly used in cancer care.

Researchers are excited about the treatments in this trial for colorectal cancer because they explore new combinations that could enhance effectiveness. Unlike standard treatments like FOLFOX or CAPOX, which rely on specific chemotherapy regimens, these investigational treatments include ivonescimab, a novel antibody that targets specific pathways involved in tumor growth. Combined with other drugs like muzastotug, leucovorin, fluorouracil, and sometimes irinotecan, these combinations aim to improve outcomes by potentially increasing the body's immune response against cancer cells. This innovative approach may lead to more effective and personalized treatment options for patients.

Research shows that combining ADG126 and ivonescimab may help treat microsatellite stable (MSS) colorectal cancer. ADG126 is a special protein that activates in the tumor area to help the immune system fight the cancer. Studies have found that patients with MSS colorectal cancer typically respond for 8 months and have an average overall survival time of 19.4 months. Ivonescimab aids by stopping the growth of blood vessels that tumors need to survive. In this trial, some participants will receive ivonescimab with chemotherapy drugs, such as those in the FOLFIRI regimen, to enhance effectiveness and possibly improve patient outcomes.¹⁶⁷⁸⁹